| SLB |
Report |
Total revenue |
IN-LINE |
pred ~$8.700B vs. cons $8.681B |
MEDIUM |
| SLB |
Report |
Adjusted diluted EPS |
IN-LINE |
pred ~$0.510 vs. cons $0.506 |
MEDIUM |
| SLB |
Report |
EBITDA |
IN-LINE |
pred ~$1.800B vs. cons $1.784B |
MEDIUM |
| SLB |
Guide |
Q3 Middle East recovery / activity |
UNKNOWN |
guide ~gradual recovery vs. cons UNVERIFIED |
LOW |
| SLB |
Guide |
FY26 capital investments |
UNKNOWN |
guide ~$2.5B vs. cons UNVERIFIED |
MEDIUM |
| SLB |
Guide |
FY26 Digital EBITDA margin |
UNKNOWN |
guide >=35% vs. cons UNVERIFIED |
MEDIUM |
| SLB |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.0% |
— |
LOW |
| SLB |
Return |
5-day cumulative residual |
+3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — relief on a de-risked setup, but limited by no expected FY re-guide |
LOW |